Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Akamis Bio

Evaluate

Thumbnail
April 27, 2022

A bad day for Molecular Partners

Setbacks hit two of the Swiss biotech’s clinical-stage darpin projects in a single day.

Thumbnail
September 23, 2019

As the heat rises, Clovis turns to radionuclides

The beleaguered drug maker has licensed a preclinical FAP-directed radiopharmaceutical, a target that has made little progress.

Article image
Vantage logo
September 13, 2018

Another must-have oncolytic virus asset for big pharma

Boehringer Ingelheim struck a deal with the oncolytic virus company Viratherapeutics in 2016, and it has clearly seen something extraordinary in the intervening two…

Vantage logo
February 21, 2018

Merck & Co makes biggest oncolytic virus bet since Amgen in 2011

Vantage logo
June 02, 2017

Sachs Forum – Deciphering the immunology combo avalanche

Vantage logo
December 23, 2016

Snippet roundup: Biogen's chief exec choice underwhelms as a big 2016 decision is delayed to 2017

Vantage logo
December 13, 2016

Setbacks fail to stifle oncolytic virus business development

Vantage logo
February 04, 2016

Imperial marches against the tide with big funding round

Vantage logo
August 18, 2015

Therapeutic focus – Cachexia research enlivened by cancer asset chase

Vantage logo
April 30, 2015

Adcom puts T-Vec on track to underwhelm

Vantage logo
September 03, 2013

Therapeutic focus – Big pharma adds weight to thin cachexia pipeline

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up